{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:53:42Z","timestamp":1791395622823,"version":"4.3.3"},"reference-count":27,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T00:00:00Z","timestamp":1666137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Annals of Medicine"],"published-print":{"date-parts":[[2022,12,31]]},"DOI":"10.1080\/07853890.2022.2133162","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T05:53:59Z","timestamp":1666158839000},"page":"2844-2848","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":24,"title":["COVID-19 treatments approved in the European Union and clinical recommendations for the management of non-hospitalized and hospitalized patients"],"prefix":"10.1080","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1149-3835","authenticated-orcid":false,"given":"Stefania","family":"Bellino","sequence":"first","affiliation":[{"name":"National Center for Drug Research and Evaluation, National Institute of Health (Istituto Superiore di Sanit\u00e0)","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,10,19]]},"reference":[{"issue":"3","key":"e_1_3_3_2_1","first-page":"e2020038","article-title":"Therapeutic strategies against COVID-19","volume":"91","author":"Esposito S","year":"2020","unstructured":"Esposito S, Gnocchi M, Gagliardi M, et\u00a0al. Therapeutic strategies against COVID-19. Acta Biomed. 2020;91(3):e2020038.","journal-title":"Acta Biomed"},{"key":"e_1_3_3_3_1","unstructured":"EMA. COVID-19 treatments. Available from https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/public-health-threats\/coronavirus-disease-covid-19\/treatments-vaccines\/covid-19-treatments."},{"key":"e_1_3_3_4_1","volume-title":"Guidance on the provision of support for medically and socially vulnerable populations in EU\/EEA countries and the United Kingdom during the COVID-19 pandemic","author":"European Centre for Disease Prevention and Control.","year":"2020","unstructured":"European Centre for Disease Prevention and Control. Guidance on the provision of support for medically and socially vulnerable populations in EU\/EEA countries and the United Kingdom during the COVID-19 pandemic, 3 July 2020. Stockholm: ECDC; 2020."},{"key":"e_1_3_3_5_1","unstructured":"Annex 1 Summary of product characteristics (Paxlovid). Available from https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/paxlovid-epar-product-information_en.pdf."},{"key":"e_1_3_3_6_1","unstructured":"Annex 1 Summary of product characteristics (Veklury). Available from https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/paxlovid-epar-product-information_en.pdf."},{"key":"e_1_3_3_7_1","unstructured":"Annex 1 Summary of product characteristics (Regkirona). Available from https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/regkirona-epar-product-information_en.pdf."},{"key":"e_1_3_3_8_1","unstructured":"Annex 1 Summary of product characteristics (Ronapreve). Available from https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ronapreve-epar-product-information_en.pdf."},{"key":"e_1_3_3_9_1","unstructured":"Annex 1 Summary of product characteristics (Xevudy). Available at https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xevudy-epar-product-information_en.pdf."},{"key":"e_1_3_3_10_1","unstructured":"Annex 1 Summary of product characteristics (Evusheld). Available from https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/evusheld-epar-product-information_en.pdf."},{"key":"e_1_3_3_11_1","unstructured":"EMA. Assessment report (molnupiravir). Available from https:\/\/www.ema.europa.eu\/en\/documents\/referral\/lagevrio-also-known-molnupiravir-mk-4482-covid-19-article-53-procedure-assessment-report_en.pdf."},{"key":"e_1_3_3_12_1","unstructured":"Annex 1 Summary of product characteristics (Kineret). Available from https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kineret-epar-product-information_en.pdf."},{"key":"e_1_3_3_13_1","unstructured":"Annex 1 Summary of product characteristics (RoActemara). Available from https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/roactemra-epar-product-information_en.pdf."},{"key":"e_1_3_3_14_1","unstructured":"Annex 1 Summary of product characteristics (Olumiant) https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/olumiant-epar-product-information_en.pdf."},{"key":"e_1_3_3_15_1","unstructured":"COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available from https:\/\/www.covid19treatmentguidelines.nih.gov\/."},{"key":"e_1_3_3_16_1","unstructured":"The National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing COVID-19. Available at https:\/\/www.nice.org.uk\/guidance\/ng191."},{"key":"e_1_3_3_17_1","unstructured":"AIFA. Reccomendations on medinicines to be used in home management of COVID-19 cases. Available from https:\/\/www.aifa.gov.it\/documents\/20142\/1269602\/EN_Raccomandazioni_AIFA_gestione_domiciliare_COVID-19_Vers7_12.04.2022.pdf."},{"key":"e_1_3_3_18_1","unstructured":"WHO. Therapeutics and COVID-19: living guidance 16 September 2022. Available from https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-therapeutics-2022.5."},{"key":"e_1_3_3_19_1","unstructured":"WHO. Living guidance for clinical management of COVID-19 23 November 2021. Available from https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-clinical-2021-2."},{"key":"e_1_3_3_20_1","unstructured":"AIFA. Treatments to be used in COVID-19 patients in a hospital setting. Available from https:\/\/www.aifa.gov.it\/documents\/20142\/1269602\/SOC_ospedaliera_04.10.2021_EN.pdf."},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00169-7"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00048-2021"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.3947\/ic.2020.52.2.142"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2207519"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/v14081706"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.220471"},{"key":"e_1_3_3_27_1","unstructured":"Queensland Government Department of Health. COVID-19 Treatment Guidelines for mild-moderate disease (Adults). July 2022."},{"key":"e_1_3_3_28_1","first-page":"S1473-3099(22)0","article-title":"Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong\u2019s omicron BA.2 wave: a retrospective cohort study","volume":"2022","author":"Wong CKH","year":"2022","unstructured":"Wong CKH, Au ICH, Lau KTK, et\u00a0al. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong\u2019s omicron BA.2 wave: a retrospective cohort study. Lancet Infect Dis. 2022;2022: S1473-3099(22)00507-2.","journal-title":"Lancet Infect Dis"}],"container-title":["Annals of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/07853890.2022.2133162","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T09:51:15Z","timestamp":1757325075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/07853890.2022.2133162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,19]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12,31]]}},"alternative-id":["10.1080\/07853890.2022.2133162"],"URL":"https:\/\/doi.org\/10.1080\/07853890.2022.2133162","relation":{},"ISSN":["0785-3890","1365-2060"],"issn-type":[{"value":"0785-3890","type":"print"},{"value":"1365-2060","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,19]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iann20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iann20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-06-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-01","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}